Immune Checkpoint Inhibitor Mediated Keratitis: A Case Study.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41173518.
- Also identified by DOI 10.1177/10966218251392777.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This case study highlights the need for palliative care (PC) clinicians to expand their knowledge of rare complications associated with Immune Checkpoint Inhibitors (ICIs) in cancer treatment. We describe a 73-year-old male with metastatic squamous cell carcinoma of the tongue who developed ICI-mediated keratitis as a side effect of pembrolizumab. The patient's preexisting opioid regimen for chronic pain complicated the management of acute ocular pain, necessitating a multidisciplinary approach. This case demonstrates how a thorough understanding of novel cancer therapies and their adverse effects is critical for PC teams to facilitate timely diagnosis, initiate effective treatment, and enhance patient outcomes.